secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001193125-25-100433
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esther Rajavelu named Spero CEO effective May 2; former CEO Sath Shukla departs
-------------------------------------------------------------------------------

- Esther Rajavelu appointed President and CEO effective May 2, 2025; nominated for board election at annual meeting.
- Rajavelu continues as CFO and Treasurer; base salary $620K, target bonus 50%, 185,000 RSUs vesting over 4 years.
- Former CEO Sath Shukla mutually separates; receives salary continuation of $615,825, cash bonus $307,913, and retention bonus $452,813.
- Company expects update on PIVOT-PO Phase 3 trial for tebipenem HBr this quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312525100433/0001193125-25-100433-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312525100433/d807820d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-100433

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer